Sana Biotechnology said a type 1 diabetes (T1D) patient received an allogeneic primary islet cell transplantation without ...

Sana Biotechnology’s hypoimmune platform enables it to make a series of genetic modifications to cells, rendering the cells ...

Sana Biotechnology Inc. CEO Steve Harr said “cool and transformative science” led to his firm’s latest strides in type 1 ...

The clinical data are highly promising for patients and provide the first evidence in humans for overcoming allogeneic and autoimmune rejection with pancreatic islet cell transplantation in type 1 ...

Sana Biotechnology has shared early data for its investigational allogeneic cell therapy being studied in one patient with ...

The following is a summary of “Identification of a pancreatic stellate cell gene signature and lncRNA interactions associated ...

Sana Biotechnology (SANA) announced initial results from an investigator-sponsored, first-in-human study transplanting UP421, an allogeneic ...

Sana Biotechnology's first-in-human study shows UP421 pancreatic islet cells surviving and functioning in type 1 diabetes ...

After years of controversy, stem cells are on the cusp of cures for conditions like epilepsy and type 1 diabetes.

It can generate billions in revenue from both acute and possibly chronic pain. If approved, it would give Vertex ...

Learn the connection between obesity and juvenile type 1 diabetes and how excess weight can complicate the management of this ...